RPG Life Sciences Limited (RPGLIFE) Price & Analysis

Compare

0 Followers

RPGLIFE Stock Chart & Stats

₹2303.55

-₹26.05(-1.12%)

At close: Jan 08 4:00 PM EST

₹2303.55

-₹26.05(-1.12%)

Day’s Range― - ―

52-Week Range₹1,767.25 - ₹2,715.90

Previous CloseN/A

Volume11.08K

Average Volume (3M)3.23K

Market Cap

₹32.59B

Enterprise Value₹29.79B

Total Cash (Recent Filing)₹2.24B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)43.4

Beta0.95

Next Earnings

Apr 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.85%

Share Statistics

EPS (TTM)13.38

Shares Outstanding16,539,015

10 Day Avg. Volume8,652

30 Day Avg. Volume3,228

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)7.03

Price to Sales (P/S)5.71

P/FCF Ratio89.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹2,470.00

Price Target Upside7.23% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High And Expanding MarginsConsistently high gross margins and a material expansion in net margin signal durable pricing power and manufacturing efficiency in its branded formulations. Sustained margin strength supports reinvestment in R&D, stable free cash generation potential, and higher long‑term returns on capital.

Very Conservative Balance SheetNear zero leverage materially reduces refinancing and interest‑rate risk, giving the company durable financial flexibility. A stronger equity base and rising ROE (~35% in FY2025) support capacity for organic investment, targeted M&A, or shareholder returns without stressing liquidity.

Multi-year Revenue Growth TrajectorySustained top‑line expansion over several years reflects successful product commercialization and market penetration across therapy areas. A diversified branded formulations portfolio and established distribution channels underpin durable revenue growth potential over the medium term.

Bears Say

Mixed Cash‑flow ConversionOperating cash flow and free cash flow trail reported earnings, and FCF has been volatile year‑to‑year. This gap suggests working capital or one‑time items affect cash quality, constraining durable funding for capex, dividends or bolt‑on M&A absent improved conversion consistency.

Unusually Strong FY2025 Step‑upA sharp single‑year jump raises sustainability concerns: if driven by non‑recurring factors, margins and earnings may mean‑revert. Reliance on one‑off gains or transient pricing advantages would pressure medium‑term profit stability absent new product wins or structural market share gains.

Limited Visibility On Short‑term Liquidity MetricsWhile leverage is minimal, absence of disclosed liquidity ratios limits assessment of working capital dynamics and near‑term cash cushions. This opacity increases uncertainty about the firm's ability to absorb operational shocks without tapping external short‑term financing.

RPG Life Sciences Limited News

RPG Life Sciences Board Clears Q3 and Nine-Month FY26 Unaudited Results

RPG Life Sciences Limited ( ($IN:RPGLIFE) ) has provided an update. RPG Life Sciences Limited has announced that...

2M ago

RPG Life Sciences Posts Steady Q3 FY26 Growth With Robust Margins

RPG Life Sciences Limited ( ($IN:RPGLIFE) ) has provided an announcement. RPG Life Sciences reported a 4.2% year-on-year...

2M ago

RPG Life Sciences Forms Wholly Owned Subsidiary RPG Active Pharma

RPG Life Sciences Limited ( ($IN:RPGLIFE) ) has issued an update. RPG Life Sciences Limited has incorporated a...

3M ago

RPG Life Sciences Unveils Strategic Leadership and Expansion Plans

RPG Life Sciences Limited ( ($IN:RPGLIFE) ) has shared an announcement. RPG Life Sciences Limited announced significant strategic...

3M ago

RPG Life Sciences Releases Q2 FY26 Earnings Call Transcript

RPG Life Sciences Limited ( ($IN:RPGLIFE) ) has provided an announcement. RPG Life Sciences Limited has released the...

5M ago

RPG Life Sciences Addresses Unusual Trading Volume

An announcement from RPG Life Sciences Limited ( ($IN:RPGLIFE) ) is now available. RPG Life Sciences Limited has...

5M ago

RPGLIFE FAQ

What was RPG Life Sciences Limited’s price range in the past 12 months?

RPG Life Sciences Limited lowest stock price was ₹1767.25 and its highest was ₹2715.90 in the past 12 months.

What is RPG Life Sciences Limited’s market cap?

RPG Life Sciences Limited’s market cap is ₹32.59B.

When is RPG Life Sciences Limited’s upcoming earnings report date?

RPG Life Sciences Limited’s upcoming earnings report date is Apr 24, 2026 which is in 41 days.

How were RPG Life Sciences Limited’s earnings last quarter?

RPG Life Sciences Limited released its earnings results on Jan 27, 2026. The company reported ₹13.38 earnings per share for the quarter, beating the consensus estimate of N/A by ₹13.38.

Is RPG Life Sciences Limited overvalued?

According to Wall Street analysts RPG Life Sciences Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does RPG Life Sciences Limited pay dividends?

RPG Life Sciences Limited pays a Notavailable dividend of ₹20 which represents an annual dividend yield of 0.85%. See more information on RPG Life Sciences Limited dividends here

What is RPG Life Sciences Limited’s EPS estimate?

RPG Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does RPG Life Sciences Limited have?

RPG Life Sciences Limited has 16,539,015 shares outstanding.

What happened to RPG Life Sciences Limited’s price movement after its last earnings report?

RPG Life Sciences Limited reported an EPS of ₹13.38 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.698%.

Which hedge fund is a major shareholder of RPG Life Sciences Limited?

Currently, no hedge funds are holding shares in IN:RPGLIFE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

RPG Life Sciences Limited

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular, diabetology, orthopedics, neuropsychiatry, respiratory, nutritional, general, urology, anti-diabetic, anti-dengue, vitamins and minerals, gynecology and pediatrics, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.

RPG Life Sciences Limited (RPGLIFE) Earnings & Revenues

Historic Earnings Reports

RPGLIFE Stock 12 Month Forecast

Average Price Target

₹2,470.00

▲(7.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1819":"₹1,819","1999":"₹1,999","2179":"₹2,179","2359":"₹2,359","2539":"₹2,539"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2470,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.47K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2470,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.47K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2470,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.47K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1819,1999,2179,2359,2539],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1820.4,1870.3692307692309,1920.3384615384616,1970.3076923076924,2020.2769230769231,2070.246153846154,2120.2153846153847,2170.1846153846154,2220.153846153846,2270.123076923077,2320.0923076923077,2370.0615384615385,2420.0307692307692,{"y":2470,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1820.4,1870.3692307692309,1920.3384615384616,1970.3076923076924,2020.2769230769231,2070.246153846154,2120.2153846153847,2170.1846153846154,2220.153846153846,2270.123076923077,2320.0923076923077,2370.0615384615385,2420.0307692307692,{"y":2470,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1820.4,1870.3692307692309,1920.3384615384616,1970.3076923076924,2020.2769230769231,2070.246153846154,2120.2153846153847,2170.1846153846154,2220.153846153846,2270.123076923077,2320.0923076923077,2370.0615384615385,2420.0307692307692,{"y":2470,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2067.67,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2233.52,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2071.09,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2153.66,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2538.75,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2350.5,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2335.6,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2283.75,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2407.15,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2228.25,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2303.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1977.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1820.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >